Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 51
Filtrar
1.
BMJ Open ; 12(10): e056801, 2022 10 17.
Artigo em Inglês | MEDLINE | ID: mdl-36253047

RESUMO

OBJECTIVE: The Brazilian state of Paraná has suffered from COVID-19 effects, understanding predictors of increased mortality in health system interventions prevent hospitalisation of patients. We selected the best models to evaluate the association of death with demographic characteristics, symptoms and comorbidities based on three levels of clinical severity for COVID-19: non-hospitalised, hospitalised non-ICU ward and ICU ward. DESIGN: Cross-sectional survey using binomial mixed models. SETTING: COVID-19-positive cases diagnosed by reverse transcription-PCR of municipalities located in Paraná State. PATIENTS: Cases of anonymous datasets of electronic medical records from 1 April 2020 to 31 December 2020. PRIMARY AND SECONDARY OUTCOME MEASURES: The best prediction factors were chosen based on criteria after a stepwise analysis using multicollinearity measure, lower Akaike information criterion and goodness-of-fit χ2 tests from univariate to multivariate contexts. RESULTS: Male sex was associated with increased mortality among non-hospitalised patients (OR 1.76, 95% CI 1.47 to 2.11) and non-ICU patients (OR 1.22, 95% CI 1.05 to 1.43) for symptoms and for comorbidities (OR 1.89, 95% CI 1.59 to 2.25, and OR 1.30, 95% CI 1.11 to 1.52, respectively). Higher mortality occurred in patients older than 35 years in non-hospitalised (for symptoms: OR 4.05, 95% CI 1.55 to 10.54; and for comorbidities: OR 3.00, 95% CI 1.24 to 7.27) and in hospitalised over 40 years (for symptoms: OR 2.72, 95% CI 1.08 to 6.87; and for comorbidities: OR 2.66, 95% CI 1.22 to 5.79). Dyspnoea was associated with increased mortality in non-hospitalised (OR 4.14, 95% CI 3.45 to 4.96), non-ICU (OR 2.41, 95% CI 2.04 to 2.84) and ICU (OR 1.38, 95% CI 1.10 to 1.72) patients. Neurological disorders (OR 2.16, 95% CI 1.35 to 3.46), neoplastic (OR 3.22, 95% CI 1.75 to 5.93) and kidney diseases (OR 2.13, 95% CI 1.36 to 3.35) showed the majority of increased mortality for ICU as well in the three levels of severity jointly with heart disease, diabetes and CPOD. CONCLUSIONS: These findings highlight the importance of the predictor's assessment for the implementation of public healthcare policy in response to the COVID-19 pandemic, mainly to understand how non-pharmaceutical measures could mitigate the virus impact over the population.


Assuntos
COVID-19 , Humanos , Masculino , Brasil/epidemiologia , Comorbidade , COVID-19/complicações , COVID-19/epidemiologia , COVID-19/mortalidade , COVID-19/terapia , Estudos Transversais , Hospitalização , Unidades de Terapia Intensiva , Pandemias , Feminino , Fatores de Risco , Adulto , Pessoa de Meia-Idade , Idoso , Modelos Estatísticos
2.
Free Radic Biol Med ; 165: 184-190, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33524532

RESUMO

Several recent reviews have suggested a role of oxidative stress in the pathophysiology of COVID-19, but its interplay with disease severity has not been revealed yet. In the present study, we aimed to investigate the association between the severity of COVID-19 and oxidative stress parameters. Clinical data of 77 patients with COVID-19 admitted to the hospital were analyzed and divided into moderate (n = 44) and severe (n = 33) groups based on their clinical condition. Production of oxidant (hydrogen peroxide) and defense antioxidants (total antioxidant capacity, reduced and oxidized glutathione, glutathione s-transferase), and oxidative damage (malondialdehyde, carbonyl, and sulfhydryl) were assessed using the serum samples. The results revealed that severe patients who presented high serum leukocyte count and CRP level stayed for a longer period in the hospital. However, there was no correlation observed between the oxidative stress parameters and degree of COVID-19 severity in the present study. In conclusion, these results indicate that the disease severity may not be a detrimental factor contributing to the changes in the redox profile of hospitalized patients with COVID-19.


Assuntos
COVID-19/metabolismo , Estresse Oxidativo/fisiologia , SARS-CoV-2/fisiologia , Adulto , Idoso , Brasil/epidemiologia , COVID-19/epidemiologia , Estudos de Coortes , Progressão da Doença , Suscetibilidade a Doenças , Feminino , Glutationa/metabolismo , Glutationa Transferase/metabolismo , Humanos , Peróxido de Hidrogênio/metabolismo , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos
3.
Arq Bras Cardiol ; 113(1): 11-17, 2019 06 27.
Artigo em Inglês, Português | MEDLINE | ID: mdl-31271596

RESUMO

BACKGROUND: Pericardium tissue allograft can be used for surgical repair in several procedures. One of the tissue engineering strategies is the process of decellularization. This process decreases immunogenic response, but it may modify the natural extracellular matrix composition and behavior. OBJECTIVE: The aim of this study was to evaluate the effectiveness of cell removal, maintenance of extracellular matrix properties and mechanical integrity of decellularized human pericardium using a low concentration solution of sodium dodecyl sulfate. METHODS: Decellularization was performed with sodium dodecyl sulfate and ethylenediaminetetraacetic acid. Histological analysis, DNA quantification, evaluation of glycosaminoglycans and collagen were performed. Biomechanical assay was performed using tensile test to compare the decellularization effects on tissue properties of tensile strength, elongation and elastic modulus. P < 0.05 was considered significant. RESULTS: There was reduction in visible nuclei present in pericardium tissue after decellularization, but it retained collagen and elastin bundles similar to fresh pericardium. The DNA contents of the decellularized pericardium were significantly reduced to less than 511.23 ± 120.4 ng per mg of dry weight (p < 0.001). The biomechanical assay showed no significant difference for fresh or decellularized tissue. CONCLUSION: The decellularization process reduces cell content as well as extracellular matrix components without changing its biomechanical properties.


Assuntos
Separação Celular/métodos , Pericárdio/citologia , Dodecilsulfato de Sódio/farmacologia , Tensoativos/farmacologia , Engenharia Tecidual/métodos , Adolescente , Adulto , Fenômenos Biomecânicos , Humanos , Pessoa de Meia-Idade , Pericárdio/efeitos dos fármacos , Medicina Regenerativa , Tecidos Suporte , Adulto Jovem
4.
Arq. bras. cardiol ; 113(1): 11-17, July 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1011228

RESUMO

Abstract Background: Pericardium tissue allograft can be used for surgical repair in several procedures. One of the tissue engineering strategies is the process of decellularization. This process decreases immunogenic response, but it may modify the natural extracellular matrix composition and behavior. Objective: The aim of this study was to evaluate the effectiveness of cell removal, maintenance of extracellular matrix properties and mechanical integrity of decellularized human pericardium using a low concentration solution of sodium dodecyl sulfate. Methods: Decellularization was performed with sodium dodecyl sulfate and ethylenediaminetetraacetic acid. Histological analysis, DNA quantification, evaluation of glycosaminoglycans and collagen were performed. Biomechanical assay was performed using tensile test to compare the decellularization effects on tissue properties of tensile strength, elongation and elastic modulus. P < 0.05 was considered significant. Results: There was reduction in visible nuclei present in pericardium tissue after decellularization, but it retained collagen and elastin bundles similar to fresh pericardium. The DNA contents of the decellularized pericardium were significantly reduced to less than 511.23 ± 120.4 ng per mg of dry weight (p < 0.001). The biomechanical assay showed no significant difference for fresh or decellularized tissue. Conclusion: The decellularization process reduces cell content as well as extracellular matrix components without changing its biomechanical properties.


Resumo Fundameto: O enxerto de pericárdio pode ser usado em muitos procedimentos de correção cirúrgica. Uma das estratégias da engenharia tecidual é o processo de descelularização. No entanto, embora esse processo diminua a resposta imunogênica, a descelularização pode modificar tanto o comportamento como a composição da matriz extracelular natural. Objetivos: Avaliar a eficácia da descelularização usando baixa concentração de dodecil sulfato de sódio na remoção celular, na manutenção das propriedades da matriz extracelular e na integridade mecânica do pericárdio humano descelularizado. Métodos: A descelularização foi realizada com dodecil sulfato de sódio e ácido etilenodiamino tetra-acético. Foi realizada análise histológica, quantificação de DNA, e avaliação de glicosaminoglicanos e colágeno. O estudo biomecânico foi conduzido pelo teste de tração para comparar os efeitos da descelularização sobre as propriedades teciduais de resistência à tração, alongamento e módulo de elasticidade. Foi considerado um valor de p < 0,05 como estatisticamente significativo. Resultados: Observou-se uma redução na quantidade de núcleos presentes no pericárdio após a descelularização, apesar de manter quantidades similares de feixes de elastina e de colágeno. As concentrações de DNA do pericárdio descelularizado foram significativamente reduzidas para menos que 511,23 ± 120,4 ng por mg de peso seco (p < 0,001). O teste biomecânico não apontou diferenças entre os tecidos fresco e descelularizado. Conclusão: A descelularização reduziu a concentração de células bem como os componentes da matriz extracelular sem afetar suas propriedades biomecânicas.


Assuntos
Humanos , Adolescente , Adulto , Pessoa de Meia-Idade , Adulto Jovem , Pericárdio/citologia , Dodecilsulfato de Sódio/farmacologia , Tensoativos/farmacologia , Separação Celular/métodos , Engenharia Tecidual/métodos , Pericárdio/efeitos dos fármacos , Fenômenos Biomecânicos , Medicina Regenerativa , Tecidos Suporte
6.
J Med Econ ; 22(2): 158-162, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30466325

RESUMO

BACKGROUND: Polymyxin B and colistin are nephrotoxic drugs used in the treatment of carbapenem-resistant Enterobacteriaceae. The aim of this study is to evaluate the burden of costs due to polymyxin associated AKI and propose a simulated break-even price for new therapies. METHODS: The pharmacoeconomic model is based on two large cross-sectional studies of polymyxin nephrotoxicity. Total direct costs in patients with and without renal failure were compared. The direct cost of each hemodialysis section (USD82.94) and daily hospital charges (USD934.85) were based on the values used in a major public hospital in the city where the clinical study was performed. The break-even price of new drugs was simulated considering eventual new drugs as effective as polymyxins, but less nephrotoxic in different percentages. Outcomes of patients after hospital discharge were not evaluated. RESULTS: Total direct cost of the group of patients who survived without AKI was significantly lower than total direct cost of the groups either with AKI or the group who died without AKI. There was a tendency of even higher costs in those who died with AKI and dialysis. Direct cost of hemodialysis was not as important as the longer hospitalization after sepsis. Considering daily cost of polymyxin is USD60, drugs with 50% less AKI could be considered cost-beneficial if the daily cost is lower than USD160. CONCLUSIONS: AKI in patients with carbapenem-resistant Enterobacteriaceae treated with polymyxin increases both length of stay in hospital and total costs.


Assuntos
Injúria Renal Aguda/induzido quimicamente , Antibacterianos/efeitos adversos , Enterobacteriáceas Resistentes a Carbapenêmicos , Infecções por Enterobacteriaceae/tratamento farmacológico , Polimixina B/efeitos adversos , Injúria Renal Aguda/economia , Adulto , Idoso , Antibacterianos/economia , Antibacterianos/uso terapêutico , Brasil , Colistina , Efeitos Psicossociais da Doença , Estudos Transversais , Farmacorresistência Bacteriana Múltipla , Infecções por Enterobacteriaceae/economia , Infecções por Enterobacteriaceae/mortalidade , Feminino , Gastos em Saúde , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Modelos Econométricos , Polimixina B/economia , Polimixina B/uso terapêutico , Diálise Renal/economia , Diálise Renal/métodos , Fatores de Risco
7.
J Infect Public Health ; 12(2): 289-291, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30031667

RESUMO

This study aimed to verify the prevalence of IgG antibodies for Toxoplasma gondii, CMV, and EBV in tissue donors from different regions of Brazil between February 2016 and July 2017. In this retrospective study, 578 donors were evaluated from different regions of Brazil. The seroprevalence of T. gondii was 61.2%, CMV was 93%, and EBV was 98.3%. The seroprevalence increased with age, from 27.8% in donors younger than 18 years of age to 67.6% in those older than 60 years of age (p<0.05). The analysis of the seroprevalence of CMV and EBV showed similar percentages (>90%) among the different states, the interior and capital of Paraná state, sex, and age. The seroprevalence of CMV, EBV and TOXO is high in all groups and age in Brazilian donors of tissues.


Assuntos
Anticorpos Antiprotozoários/sangue , Anticorpos Antivirais/sangue , Infecções por Citomegalovirus/epidemiologia , Infecções por Vírus Epstein-Barr/epidemiologia , Doadores de Tecidos , Toxoplasmose/epidemiologia , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Brasil , Citomegalovirus/imunologia , Feminino , Herpesvirus Humano 4/imunologia , Humanos , Imunoglobulina G/sangue , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Estudos Soroepidemiológicos , Topografia Médica , Toxoplasma/imunologia , Adulto Jovem
8.
Rev Iberoam Micol ; 35(2): 63-67, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29605496

RESUMO

BACKGROUND: Posaconazole is used for the prophylaxis of invasive fungal disease (IFD). Previous studies have shown it to be cost-effective compared to fluconazole/itraconazole. However, posaconazole has never been economically evaluated in developing countries. AIMS: The aim of the present study was to perform a cost-effectiveness analysis of posaconazole compared to fluconazole in public (SUS) and private hospitals (PHS) in Brazil. METHODS: A cost-effectiveness simulation was conducted on the basis of a pivotal study on the use of posaconazole in acute myeloid leukemia (AML) patients, adjusting the costs to Brazilian data. RESULTS: A pharmacoeconomic analysis was performed on a hypothetical sample of 100 patients in each drug group. The total cost of posaconazole use alone was USD$ 220,656.31, whereas that for fluconazole was USD$ 83,875.00. Our results showed that patients with IFD remain hospitalized for an additional 12 days, at an average cost of USD$ 850.85 per patient per day. The total money spent by PHS for 100 patients for 100 days was USD$ 342,318.00 for the posaconazole group and USD$ 302,039.00 for the fluconazole group. An analysis of sensitivity (10%) revealed no intergroup difference. CONCLUSIONS: In Brazil posaconazole is cost-effective, and should be considered for the prophylaxis of patients with AMD/myelodysplasia (AML/MDS) undergoing chemotherapy.


Assuntos
Antifúngicos/economia , Custos de Medicamentos/estatística & dados numéricos , Hospitais Privados/economia , Hospitais Públicos/economia , Micoses/prevenção & controle , Triazóis/economia , Brasil , Neutropenia Febril Induzida por Quimioterapia/complicações , Efeitos Psicossociais da Doença , Análise Custo-Benefício , Países em Desenvolvimento/economia , Fluconazol/economia , Humanos , Hospedeiro Imunocomprometido , Itraconazol/economia , Leucemia Mieloide Aguda/complicações , Micoses/economia , Micoses/etiologia
9.
Med Mycol ; 56(4): 406-415, 2018 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-29420820

RESUMO

Candidemia is the main invasive fungal disease among hospitalized patients. Several breakthrough candidemia (BrC) cases have been reported, but few studies evaluate the epidemiology, risk factors, molecular characterization, antifungal susceptibility profile and outcome of those patients, especially in developing countries and including patients using broad spectrum antifungals. We conducted a retrospective study from 2011 to 2016, including patients aged 12 years or older with candidemia. Epidemiological characteristics and risk factors for candidemia were evaluated and compared with patients with BrC using univariate and multivariate analysis. Sequential Candida isolates from BrC were identified by internal transcribed spacer sequencing, genotyped with amplified fragment length polymorphism fingerprinting (AFLP), and tested for antifungal susceptibility. From 148 candidemia episodes, 27 breakthrough episodes (18%) were identified, with neutropenia and mucositis being independent risk factors for BrC. Candida non-albicans was more frequent in the BrC group (P < .001). AFLP showed high correlation with conventional methods of identification among breakthrough isolates and a high genetic similarity among isolates from the same patient was observed. C. albicans was the most susceptible species with low MIC values for all antifungal agents tested. In contrast, we found isolates of C. glabrata, C. parapsilosis and C. tropicalis resistant to triazoles and echinocandins. In conclusion, BrC occurred mainly in severely immunosuppressed patients, with neutropenia and mucositis. Mortality did not differ between the groups. Candida non-albicans species were more recovered from BrC, with C. albicans being the most susceptible to antifungals.


Assuntos
Antibioticoprofilaxia , Antifúngicos/farmacologia , Antifúngicos/uso terapêutico , Candida/efeitos dos fármacos , Candidemia/tratamento farmacológico , Doença Aguda , Adolescente , Adulto , Análise do Polimorfismo de Comprimento de Fragmentos Amplificados , Brasil , Candida/classificação , Candida/isolamento & purificação , Candidemia/diagnóstico , Candidemia/epidemiologia , Candidemia/microbiologia , Criança , Farmacorresistência Fúngica/efeitos dos fármacos , Feminino , Humanos , Infecções Fúngicas Invasivas/tratamento farmacológico , Infecções Fúngicas Invasivas/prevenção & controle , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Profilaxia Pré-Exposição , Estudos Retrospectivos , Fatores de Risco , Resultado do Tratamento , Adulto Jovem
11.
Trop Med Int Health ; 22(5): 539-546, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28196298

RESUMO

OBJECTIVE: The most common form of transmitting human brucellosis is through contaminated food or direct contact with infected animals. Human-to-human transmission (HHT) has been described as isolated case reports. The aim of this systematic review was to describe all cases of HHT of human brucellosis reported in the medical literature. METHODS: A literature search was conducted using PubMed, Scopus and Scielo databases using specific search terms published until March 2016. Two investigators independently determined study eligibility. All clinical data were evaluated to construct a table comprising the most important clinical aspects, age, gender, confirmed infection and detection method, transmission method and HHT confirmation and potential source of infection for human transmission. No statistical method was employed in this study. RESULTS: The initial search resulted in 615 publications, but only 35 were included. 45 brucellosis HHT cases were identified. 61% of patients who acquired brucellosis from another human were <1 year old (newborn and breastfeeding). Other cases include sexual transmission, blood transfusion, bone marrow transplantation and aerosol from an infected patient. Most patients (40/45) presented symptoms upon diagnosis. Diagnostic tests included culture, molecular methods and serum testing. CONCLUSION: Human brucellosis is a disease liable to transmission between humans by placental barrier, lactation, sexual and tissues such as blood and bone marrow. The indication for screening in tissue banks, transplants, blood and pregnancy is not yet established.


Assuntos
Brucella , Brucelose/transmissão , Transfusão de Sangue , Transplante de Medula Óssea , Aleitamento Materno , Brucelose/microbiologia , Feminino , Humanos , Gravidez , Infecções Sexualmente Transmissíveis
12.
Braz. j. infect. dis ; 21(1): 1-6, Jan.-Feb. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-839191

RESUMO

Abstract Background: The ideal therapeutic option for ventilator associated pneumonia caused by carbapenem-resistant Enterobacteriaceae is not defined. The aim of this study was to assess mortality-associated risk factors in patients with VAP by CRE and determine the outcome of several treatment options. Methods: This was a retrospective study performed in two tertiary hospitals involving patients with VAP caused by CRE between January 2010 and August 2014. The outcomes were mortality within 30 days of VAP diagnosis and overall mortality during hospital admission. Risk factors for mortality were assessed by comparing variables of survivors and non-survivors. Results: One hundred and twelve patients with CRE-VAP were included, 73 (65%) male, median age 56 years. The 30-day mortality was 57.1% and the overall hospital mortality was 67%. In the binary logistic regression analysis, only age >50 years was independently associated to increased mortality. Polymyxin was the most used drug (47.5%), followed by tigecycline (29.2%) and aminoglycosides (2.4%). Combined therapy with two active drugs was used by 17 patients (20.8%). No therapeutic option was independently associated to survival. However, combined therapy with two active drugs was superior to the therapy with a single active drug when inappropriate therapy was the comparator (p = 0.044). The addition of carbapenem was not associated with increased survival. Conclusion: The best therapeutic option for VAP by CRE is still not completely defined, but the therapy with at least two active drugs was superior in this study.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Carbapenêmicos/uso terapêutico , Farmacorresistência Bacteriana , Infecções por Enterobacteriaceae/mortalidade , Pneumonia Associada à Ventilação Mecânica/mortalidade , Antibacterianos/uso terapêutico , Fatores de Tempo , Modelos Logísticos , Estudos Transversais , Estudos Retrospectivos , Fatores de Risco , Resultado do Tratamento , Mortalidade Hospitalar , Estatísticas não Paramétricas , Enterobacter aerogenes/efeitos dos fármacos , Quimioterapia Combinada/mortalidade , Pneumonia Associada à Ventilação Mecânica/microbiologia , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Klebsiella pneumoniae/efeitos dos fármacos
13.
Braz J Infect Dis ; 21(1): 1-6, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27821248

RESUMO

BACKGROUND: The ideal therapeutic option for ventilator associated pneumonia caused by carbapenem-resistant Enterobacteriaceae is not defined. The aim of this study was to assess mortality-associated risk factors in patients with VAP by CRE and determine the outcome of several treatment options. METHODS: This was a retrospective study performed in two tertiary hospitals involving patients with VAP caused by CRE between January 2010 and August 2014. The outcomes were mortality within 30 days of VAP diagnosis and overall mortality during hospital admission. Risk factors for mortality were assessed by comparing variables of survivors and non-survivors. RESULTS: One hundred and twelve patients with CRE-VAP were included, 73 (65%) male, median age 56 years. The 30-day mortality was 57.1% and the overall hospital mortality was 67%. In the binary logistic regression analysis, only age >50 years was independently associated to increased mortality. Polymyxin was the most used drug (47.5%), followed by tigecycline (29.2%) and aminoglycosides (2.4%). Combined therapy with two active drugs was used by 17 patients (20.8%). No therapeutic option was independently associated to survival. However, combined therapy with two active drugs was superior to the therapy with a single active drug when inappropriate therapy was the comparator (p=0.044). The addition of carbapenem was not associated with increased survival. CONCLUSION: The best therapeutic option for VAP by CRE is still not completely defined, but the therapy with at least two active drugs was superior in this study.


Assuntos
Antibacterianos/uso terapêutico , Carbapenêmicos/uso terapêutico , Farmacorresistência Bacteriana , Infecções por Enterobacteriaceae/mortalidade , Pneumonia Associada à Ventilação Mecânica/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Quimioterapia Combinada/mortalidade , Enterobacter aerogenes/efeitos dos fármacos , Feminino , Mortalidade Hospitalar , Humanos , Klebsiella pneumoniae/efeitos dos fármacos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Pneumonia Associada à Ventilação Mecânica/microbiologia , Estudos Retrospectivos , Fatores de Risco , Estatísticas não Paramétricas , Fatores de Tempo , Resultado do Tratamento
14.
Antimicrob Agents Chemother ; 60(4): 2443-9, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26856846

RESUMO

Nephrotoxicity is the main adverse effect of colistin and polymyxin B (PMB). It is not clear whether these two antibiotics are associated with different nephrotoxicity rates. We compared the incidences of renal failure (RF) in patients treated with colistimethate sodium (CMS) or PMB for ≥48 h. A multicenter prospective cohort study was performed that included patients aged ≥18 years. The primary outcome was renal failure (RF) according to Risk, Injury, Failure, Loss, and End-stage renal disease (RIFLE) criteria. Multivariate analysis with a Cox regression model was performed. A total of 491 patients were included: 81 in the CMS group and 410 in the PMB group. The mean daily doses in milligrams per kilogram of body weight were 4.2 ± 1.3 and 2.4 ± 0.73 of colistin base activity and PMB, respectively. The overall incidence of RF was 16.9% (83 patients): 38.3% and 12.7% in the CMS and PMB groups, respectively (P< 0.001). In multivariate analysis, CMS therapy was an independent risk factor for RF (hazard ratio, 3.35; 95% confidence interval, 2.05 to 5.48;P< 0.001) along with intensive care unit admission, higher weight, older age, and bloodstream and intraabdominal infections. CMS was also independently associated with a higher risk of RF in various subgroup analyses. The incidence of RF was higher in the CMS group regardless of the patient baseline creatinine clearance. The development of RF during therapy was not associated with 30-day mortality in multivariate analysis. CMS was associated with significantly higher rates of RF than those of PMB. Further studies are required to confirm our findings in other patient populations.


Assuntos
Injúria Renal Aguda/induzido quimicamente , Antibacterianos/efeitos adversos , Colistina/análogos & derivados , Falência Renal Crônica/induzido quimicamente , Polimixina B/efeitos adversos , Injúria Renal Aguda/tratamento farmacológico , Injúria Renal Aguda/mortalidade , Injúria Renal Aguda/patologia , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/administração & dosagem , Peso Corporal , Colistina/administração & dosagem , Colistina/efeitos adversos , Esquema de Medicação , Feminino , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Negativas/crescimento & desenvolvimento , Bactérias Gram-Negativas/patogenicidade , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Infecções por Bactérias Gram-Negativas/microbiologia , Infecções por Bactérias Gram-Negativas/mortalidade , Infecções por Bactérias Gram-Negativas/patologia , Humanos , Unidades de Terapia Intensiva , Infecções Intra-Abdominais/tratamento farmacológico , Infecções Intra-Abdominais/microbiologia , Infecções Intra-Abdominais/mortalidade , Infecções Intra-Abdominais/patologia , Falência Renal Crônica/tratamento farmacológico , Falência Renal Crônica/mortalidade , Falência Renal Crônica/patologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Polimixina B/administração & dosagem , Estudos Prospectivos , Infecções Respiratórias/tratamento farmacológico , Infecções Respiratórias/microbiologia , Infecções Respiratórias/mortalidade , Infecções Respiratórias/patologia , Fatores de Risco , Análise de Sobrevida
15.
J Med Microbiol ; 64(9): 951-959, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26220079

RESUMO

Acinetobacter are among the most common bacteria isolated in hospital infections, especially in developing countries. Multi-drug, extended-drug or pan-drug resistance makes treatment a real medical challenge. In the present review, the authors describe clinical and experimental data in order to present different current and potential future strategies to treat infections caused by multi-drug-resistant Acinetobacter. The therapeutic options for carbapenem-resistant Acinetobacter are scarce, and the current options have poor pharmacokinetic aspects and several side effects. Combined therapy has been an alternative for multi-drug-resistant Acinetobacter. However, this issue is always controversial. In some studies combined therapy has shown superiority for some strains of Acinetobacter in animal models and in vitro studies. However, studies with humans are scarce and too poor quality to suggest the best approach for the treatment of infections caused by multi-drug-resistant Acinetobacter baumannii.


Assuntos
Infecções por Acinetobacter/tratamento farmacológico , Infecções por Acinetobacter/microbiologia , Acinetobacter baumannii/efeitos dos fármacos , Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Farmacorresistência Bacteriana Múltipla , Humanos
17.
Pesqui. vet. bras ; 35(3): 258-264, 03/2015. tab, graf
Artigo em Português | LILACS | ID: lil-751983

RESUMO

Este estudo verificou o perfil de resistência aos antimicrobianos entre isolados de Escherichia coli de frangos de corte de criação intensiva e de subsistência e dos respectivos tratadores e a similaridade genotípica entre isolados de E.coli de frangos de corte de criação intensiva e isolados de E. coli de tratadores de frangos de criação intensiva pela técnica de Eletroforese em Gel de Campo Pulsado (PFGE). 60 amostras de fezes de frangos de criação intensiva, 60 de frangos de corte de criação de subsistência (caipira) e 20 amostras dos tratadores de frangos de criação intensiva e 20 de tratadores de frangos de criação de subsistência. E. coli foram isoladas, identificadas e submetidas ao teste de suscetibilidade a 12 antimicrobianos. Pela PFGE foram analisados 24 isolados de E. coli de frangos de corte de criação intensiva e oito de tratadores. Em isolados E. coli de frangos de criação intensiva a resistência para a ampicilina foi de 100%, cefotaxima 43%, ceftriaxona 48%, ácido nalidíxico 62%, enrofloxacina 23%, ciprofloxacina 23%, tetraciclina 83% e 45% para trimetoprim-sulfametoxazol. Nos isolados de frangos de criação de subsistência foi de 20%, 0%, 0%, 5%, 2%, 4%, 33% e 8%, respectivamente...


This study examined the profile of antimicrobial resistance among isolates of Escherichia coli from poultry intensive farming and free-range systems and their farmers. For technique of Gel Electrophoresis Pulsed Field (PFGE) examined the similarity between isolates from poultry intensive farming and their farmers. From 60 samples of poultry feces from intensive farming systems, 60 of free-range extensive systems and 20 of farmers of each segment, the E. coli was isolated and submitted to the test of susceptability to 12 antimicrobials. 24 isolates of E. coli of poultry from intensive farming systems and eight E. coli isolates from farmers poultry intensive farming were analyzed via technique of PFGE. In intensive farming systems poultry, 100% resistence to ampicillin was verified, 43% to cefotaxime, 48% to ceftriaxone, 62% to nalidixic acid, 23% to enrofloxacin, 23% to ciprofloxacin, 83% to tetracycline and 45% to trimetroprim-sulfametoxazol. In the strains of free-range extensive systems, resistance was 20%, 0%, 0%, 5%, 2%, 4%, 33% and 8%, respectively...


Assuntos
Animais , Resistência a Ampicilina , Aves Domésticas/microbiologia , Escherichia coli/isolamento & purificação , beta-Lactamas , Resistência Microbiana a Medicamentos
18.
Braz J Infect Dis ; 19(3): 324-7, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25722130

RESUMO

BACKGROUND: Enterobacter is a common nosocomial microorganism and its carbapenem's resistance has increased. The management of these cases is unclear. OBJECTIVE: We evaluated 16 patients with KPC-producing Enterobacter aerogenes infections, detailing the site of infection, therapy, clinical and epidemiological data. METHODS: A retrospective and descriptive study. Clinical data were revised and KPC-2 detection was by molecular methods. Risk factors associated with mortality were compared using appropriate tests according to variable type with a significance level of 0.05. RESULTS: The 30-day mortality rate was 37.5% with no association with inadequate treatment. Age (p=0.004) and Charlson score of comorbidities (p=0.048) were independent risk factors associated with death in the multivariate analysis. The odds ratio for age >43 years was 3.00 (95% CI: 1.02-9.32) and for Charlson score >3 was 2.00 (95% CI: 1.08-3.71). Five strains were pan-resistant based on automated susceptibility tests. All patients were treated with monotherapy. CONCLUSION: The clinician should be alert to carbapenem-resistant Enterobacteriaceae infection in older patients with comorbidities. The mortality is high and we believe that prompt and adequate therapy must be employed.


Assuntos
Antibacterianos/farmacologia , Enterobacter aerogenes/efeitos dos fármacos , Enterobacter aerogenes/enzimologia , Infecções por Enterobacteriaceae/microbiologia , beta-Lactamases/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Infecções por Enterobacteriaceae/mortalidade , Feminino , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Gravidez , Estudos Retrospectivos , Fatores de Risco , Adulto Jovem , beta-Lactamases/efeitos dos fármacos
19.
J Infect Chemother ; 21(4): 316-8, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25585523

RESUMO

Carbapenem-resistant Enterobacteriaceae (CRE) is a major international health problem, and its identification in developing countries is based exclusively on phenotypic methods. The aim of this study was to assess the sensitivity and related parameters of the modified Hodge test (MHT). The assessment was performed in a large number of isolates obtained from different hospitals in several cities of a south Brazilian state. Bacterial species were identified using an automated method. The MHT was performed according to the guidelines set by the CLSI. The gene blaKPC was amplified in order to confirmation CRE expression. The sensitivity, specificity, positive, and negative predictive values were calculated. A total of 942 isolates were submitted to the reference laboratory for confirmation; 143 showed a negative MHT (15.18%) result, while 784 were positive (83.23%), and 15 samples displayed an indeterminate MHT (1.59%) result. All samples expressed the KPC-2 enzyme. Sensitivity, specificity, positive, and negative predictive percentiles were 99%, 89%, 98%, and 99% respectively. We conclude that the modified Hodge test is a reliable test for the prediction of KPC-producing bacteria.


Assuntos
Antibacterianos/farmacologia , Carbapenêmicos/farmacologia , Infecções por Enterobacteriaceae/microbiologia , Enterobacteriaceae , Tipagem Molecular/métodos , Resistência beta-Lactâmica/genética , Proteínas de Bactérias/genética , Brasil/epidemiologia , Enterobacteriaceae/efeitos dos fármacos , Enterobacteriaceae/genética , Infecções por Enterobacteriaceae/epidemiologia , Humanos , Fenótipo , Valor Preditivo dos Testes , beta-Lactamases/genética
20.
Am J Infect Control ; 43(2): 137-40, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25541337

RESUMO

BACKGROUND: Klebsiella pneumoniae carbapenemase-producing K pneumoniae (KPC-KP) outbreaks have been reported in many countries, including Brazil. The incidence of KPC-KP infection has increased in the first semester of 2011 in Curitiba, the capital of Parana, in Southern Brazil.The aim of this study was to characterize the infections and clonal diversity of KPC-KP isolates from several institutions in Curitiba. METHODS: KPC-KP from several clinical samples and rectal swabs taken between April 2010 and July 2012 were included. One isolate per patient was evaluated. All isolates were submitted to polymerase chain reaction (PCR) for blaKPC. The genetic relatedness was evaluated using strain clustering by an automated repetitive extragenic palindromic (rep) PCR-based typing system. RESULTS: There were 641 samples that were positive for K pneumoniae carbapenemase-2 carbapenemase. There were 129 samples randomly selected for clonality evaluation. PCR and strain clustering by the automated rep PCR-based typing system identified 7 clones (A-C and E-H). Clone E was identified in only 1 hospital, and all other clones were found in >2 hospitals. Clones C and G were the most disseminated among hospitals. The infection and colonization occurred in 14 out of the 32 main hospitals in town. Similar clones were found in 2 hospitals that are administered by the same group. Another clone (H) was found in 2 hospitals receiving patients from the same municipal emergency unit. CONCLUSION: The KPC-KP outbreak in Curitiba is polyclonal, and the source is unknown. Some hospitals share the same clones.


Assuntos
Proteínas de Bactérias/metabolismo , Farmacorresistência Bacteriana , Regulação Bacteriana da Expressão Gênica/fisiologia , Regulação Enzimológica da Expressão Gênica/fisiologia , Infecções por Klebsiella/epidemiologia , Klebsiella pneumoniae/enzimologia , beta-Lactamases/metabolismo , Antibacterianos/farmacologia , Proteínas de Bactérias/classificação , Proteínas de Bactérias/genética , Brasil , Hospitais , Humanos , Infecções por Klebsiella/microbiologia , Klebsiella pneumoniae/genética , Klebsiella pneumoniae/metabolismo , Epidemiologia Molecular , beta-Lactamases/classificação , beta-Lactamases/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...